A VIRAL EXPOSURE SIGNATURE FOR DETECTION OF EARLY STAGE HEPATOCELLULAR CARCINOMA Read more about A VIRAL EXPOSURE SIGNATURE FOR DETECTION OF EARLY STAGE HEPATOCELLULAR CARCINOMA US Application 17/766,015Filed on 2022-04-01
A VIRAL EXPOSURE SIGNATURE FOR DETECTION OF EARLY STAGE HEPATOCELLULAR CARCINOMA Read more about A VIRAL EXPOSURE SIGNATURE FOR DETECTION OF EARLY STAGE HEPATOCELLULAR CARCINOMA China202080071446.7Filed on 2020-10-09
T CELL RECEPTORS RECOGNIZING HLA-A1-RESTRICTED MAGE-A3 Read more about T CELL RECEPTORS RECOGNIZING HLA-A1-RESTRICTED MAGE-A3 US Application 17/691,569Filed on 2022-03-10
Intracellular Genomic Transplant and Methods of Therapy Read more about Intracellular Genomic Transplant and Methods of Therapy US Application 17/674,378Filed on 2022-02-17
Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab Read more about Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab US Application 16/077,720Filed on 2018-08-13
Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab Read more about Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab Russia2018131377Filed on 2017-02-14
Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab Read more about Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab Mexico2018009867Filed on 2017-02-14
Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab Read more about Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab Morocco17753704.0Filed on 2017-02-14
Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab Read more about Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab South Korea2018-7024215Filed on 2017-02-14
Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab Read more about Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab Japan2021-064539Filed on 2017-02-14